Form 4: Kura Oncology COO Granted 50,000 RSUs and 100,000 Options

Kura Oncology's Chief Operating Officer, Kathleen Ford, was granted 50,000 Restricted Stock Units and options to purchase 100,000 shares of common stock.

Summary

• Kathleen Ford, Chief Operating Officer of Kura Oncology, Inc., acquired 50,000 shares of common stock through a Restricted Stock Unit (RSU) grant on January 2, 2026.
• These RSUs were granted at a price of $0 and will vest in four equal annual installments starting January 26, 2027, through January 26, 2030.
• Ford also acquired options to purchase 100,000 shares of common stock on January 2, 2026, with an exercise price of $10.335.
• These options vest in 48 equal monthly installments commencing on the grant date and expire on January 1, 2036.
• Following these transactions, Ford beneficially owns 155,373 shares of common stock and 100,000 options directly.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally a positive signal, indicating confidence in the executive's continued contribution and aligning their interests with long-term shareholder value. It's a standard compensation practice, hence not extremely high, but certainly positive.

Positives

• Grant of 50,000 Restricted Stock Units (RSUs) to a key executive, aligning management's interests with shareholder value.
• Grant of options to purchase 100,000 shares, providing long-term incentive for the Chief Operating Officer.
• The vesting schedules for both RSUs and options demonstrate a commitment to long-term executive retention and performance.

Future Outlook

The equity grants with multi-year vesting schedules indicate an expectation of continued executive tenure and long-term value creation for Kura Oncology.

Industry Context

Equity grants to key executives like the Chief Operating Officer are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize top talent, aligning their performance with the company's long-term strategic goals and shareholder interests.

Comparison to Industry Standards

• The grant of RSUs and stock options with multi-year vesting schedules is a common compensation structure for executive leadership in the biotech sector, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which use similar long-term incentive plans to retain key personnel and drive innovation.

Stakeholder Impact

• Shareholders: The grants align the COO's long-term interests with shareholder value creation, potentially leading to improved performance and stock appreciation.
• Employees: May signal stability in leadership and a commitment to long-term incentives for key personnel.

Next Steps

• The 50,000 Restricted Stock Units will vest in four equal annual installments on January 26, 2027, January 26, 2028, January 26, 2029, and January 26, 2030.
• The options to purchase 100,000 shares will vest in 48 equal monthly installments commencing on the grant date of January 2, 2026.

Key Dates

Recommendation

While the equity grants to the COO are a positive sign of management alignment and retention, a Form 4 filing primarily reports insider transactions and does not provide sufficient fundamental financial or operational data to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance for existing investors, indicating stable executive incentives, but does not present new information for a strong directional call.

Keywords

Kura Oncology, KURA, Kathleen Ford, COO, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Insider Transaction, SEC Form 4, Biotechnology, Pharmaceuticals